Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 20/20 | 0.66 |
| ▸ | EED | O75530 | 2/20 | 0.65 |
| ▸ | RBBP4 | Q09028 | 2/20 | 0.65 |
| ▸ | SUZ12 | Q15022 | 2/20 | 0.65 |
| ▸ | RBBP7 | Q16576 | 2/20 | 0.65 |
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10256644 | 0.92 | EZH2 (0.71) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL10259704 | 0.90 | EZH2 (0.67) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL10257356 | 0.89 | EZH2 (0.74) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL18800377 | 0.89 | EZH2 (0.71) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL12684012 | 0.89 | EZH2 (0.69) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL18800338 | 0.89 | EZH2 (0.70) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL10255850 | 0.89 | EZH2 (0.69) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL12499149 | 0.88 | EZH2 (0.70) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL19958888 | 0.87 | EZH2 (0.67) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL21418333 | 0.87 | EZH2 (0.72) | EZH2EEDRBBP4SUZ12RBBP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140343056-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140343056-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343056-A1 | AZAINDAZOLES | AZI2, MKI67, DNMT1 | EZH2 58/4885EED 454/4885RBBP4 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.